---
title: Plasma linoelaidyl carnitine levels positively correlated with symptom improvement
  in olanzapine-treated first-episode drug-na√Øve schizophrenia
date: '2022-07-11'
linkTitle: http://rd.springer.com/10.1007/s11306-022-01909-4
source: Latest Results for Metabolomics
description: ' <h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section
  id-a-sec1"> <h3 class="a-plus-plus">Introduction</h3> <p class="a-plus-plus">Olanzapine
  (OLA) is one of the most commonly used second-generation antipsychotics for the
  treatment of schizophrenia. However, the heterogeneity of therapeutic response to
  OLA among schizophrenia patients deserves further exploration. The role of carnitine
  in the clinical response to OLA monotherapy remains unclear.</p> </span> <span class="a-plus-plus
  abstract-section id-a-sec2"> <h3 class="a-plus-plus">Objectives</h3> <p ...'
---
 <h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section id-a-sec1"> <h3 class="a-plus-plus">Introduction</h3> <p class="a-plus-plus">Olanzapine (OLA) is one of the most commonly used second-generation antipsychotics for the treatment of schizophrenia. However, the heterogeneity of therapeutic response to OLA among schizophrenia patients deserves further exploration. The role of carnitine in the clinical response to OLA monotherapy remains unclear.</p> </span> <span class="a-plus-plus abstract-section id-a-sec2"> <h3 class="a-plus-plus">Objectives</h3> <p ...